Abstract | PURPOSE: METHODS: Key clinical trials supporting the use of ACE inhibitors and ARBs in chronic kidney disease are discussed. Recent developments in our understanding of RAAS biology and the use of direct renin inhibition are reviewed in the context of their potential impact on the prevention and management of chronic kidney disease. RESULTS: CONCLUSIONS:
|
Authors | Christian W Mende |
Journal | Cardiovascular drugs and therapy
(Cardiovasc Drugs Ther)
Vol. 24
Issue 2
Pg. 139-49
(Apr 2010)
ISSN: 1573-7241 [Electronic] United States |
PMID | 20490905
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Renin
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Animals
- Humans
- Renal Insufficiency, Chronic
(drug therapy)
- Renin
(antagonists & inhibitors)
|